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Treatment of Malignant Pleural Mesothelioma with
Carboplatin, Liposomized Doxorubicin, and Gemcitabine
A Phase II Study
Gunnar Hillerdal, MD, PhD,* Jens Benn Sorensen, MD, PhD,† Stein Sundstro¨m, MD,‡
Henrik Riska, MD, PhD,§ Anders Vikstro¨m, MD, and Anders Hjerpe, MD, PhD¶
Background:Malignant pleural mesothelioma has a poor prognosis
and there is limited effect of treatment. The Nordic Mesothelioma
groups decided in the year 2000 to investigate a combination of
liposomized doxorubicin, carboplatin, and gemcitabine for this dis-
ease in a phase II study.
Methods: From January 2001, to December 2003, 173 evaluable
patients with biopsy-verified malignant mesothelioma were in-
cluded. Two patients were lost to follow-up, but all the others were
followed for at least 4 years or until death.
Results: Toxicity was fairly low. There were 56 responses (32.4%),
of which 2 were complete; the median time to progression was 8.6
months, and the median overall survival was 13 months. Some
patients had their responses 4 to 6 months after last treatment. For
116 patients with epitheloid subtype, median survival was 17
months. A subgroup of these patients with good performance status,
early stage, and age 70 years or less, showed a median survival of 22
months.
Conclusion: The treatment yields good results with a high number
of responses and long survival, and a low toxicity. The long survival
of the epitheloid subgroup with good prognostic factors is as good as
or even better than some studies on “radical” surgery or multimodal
treatment, underlining the need of randomized studies to evaluate
such treatment options.
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Malignant pleural mesothelioma (MPM) is a compara-tively rare disease with a poor prognosis. The main
cause is former exposure to asbestos, mainly occupational but
also paraoccupational or environmental. The incidence mir-
rors the use of asbestos in the society three to five decades
earlier.1 Annually, there are approximately 300 cases in the
Nordic countries, about 100 patients in Sweden and Den-
mark, respectively, 60 in Finland, and 50 in Norway.
Since many years, there have been active mesothelioma
study groups in these countries, cooperating in treatment
studies. The present study was planned in year 2000, when
many small studies with chemotherapy treatment had been
reported, usually showing a disappointingly low response rate
around 20% or no effect at all, and no evidence of effect on
survival. It was difficult to draw conclusions regarding the
value of various drugs, since inclusion and remission criteria
were different between studies. The median survival after diag-
nosis was less than a year, and treatment in different centers
varied from aggressive surgery sometimes combined with che-
motherapy to merely supportive and palliative care.2–7
Doxorubicin had shown some efficacy against mesothe-
lioma, but due to the side effects it had not gained wider
acceptance. Liposomal-encapsulated doxorubicin is much
less toxic and responses had been reported in mesothelioma.8,9 A
study with this drug by the Nordic Mesothelioma Group was
just finished, and the median time to progression of the tumor
and survival was superior to most studies published until
then.10 A phase II European Organization for Research and
Treatment of Cancer study had also been published,11 show-
ing a median survival of 13 months and only mild toxicity.
The group therefore felt that there were good reasons to
evaluate this drug in combination with other cytostatics.
Carboplatin, as a single drug against mesothelioma, had
also been reported to have some effect,11-13 and cisplatin in
combination with gemcitabine in a small study had shown a
high response rate though not very long survival.14 Thus, the
Nordic Mesothelioma Group decided to investigate a combi-
nation of pegylated liposomal-encapsulated doxorubicin,
gemcitabine, and carboplatin in MPM in a phase II study,
with the hope of adding a long time to progression to a high
response rate.
A small pilot study on eight patients was performed at two
centers (Karolinska University Hospital in Stockholm and the
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University Hospital of Linkoping, Sweden). The dosages were
well tolerated, and promising responses were seen.
After the trial had started and a number of patients had
been followed for more than three courses, it was found that
most patients had to have a dose reduction after the third or
fourth cycle. An amendment to the protocol was then agreed
upon, stating that after cycle three, all patients should have a
dose reduction.
The study was initially planned to include only about
45 patients. However, due to the comparatively very high
response rate that was achieved–better than any until then
published results–it was accepted by the Ethical Committees
in the participating countries to include more patients, since
no standard treatment existed, i.e., the regimen was the best
available alternative at the time and most of the physicians
participating in the study would continue to use it even if the
study would be closed to inclusion. Consequently, the study
was extended twice, ending only when the Pemetrexed
study15 was presented.
PATIENTS AND METHODS
Patients
All patients with pleural malignant mesothelioma diag-
nosed at or referred to the participating centers who fulfilled
the criteria, were offered enrollment in the study. Nineteen
centers in the 4 countries joined in the study, 10 referral
centers and 9 smaller ones.
End-Points
The aim of the study was to evaluate the efficacy and
safety of the combination as therapy for patients with MPM
not suitable for surgery. The primary response parameter was
objective response rate. Secondary endpoints included time to
progression (TTP), overall survival, toxicity, health-related
Quality of Life (QoL), and performance status. The goal was
to follow all patients until death or at least 4 years from first
treatment.
Inclusion and Exclusion Criteria
Histologic verification of MPM was the primary crite-
rion for inclusion in the study. The inclusion and exclusion
criteria can be seen in Table 1.
Clinical and Pathologic Investigations
The pretreatment evaluation included clinical investi-
gation with medical history and penetration of any possible
exposure to asbestos. Adequate biopsy material was obtained,
if needed obtained by thoracoscopy or thoracotomy. The
diagnosis was primarily made by the local pathologist, which
was sufficient for inclusion. Later, a panel of pathologists in
each country assessed the biopsy. Definite or probable MPM
were accepted, but doubtful cases were excluded.
Radiology
Chest roentgenogram with high kV technique, posterio-
anterior and lateral, was obtained and computed tomography
(CT) scan of the thorax with the upper abdomen (including
the lowest level of the kidneys) was performed in a standard-
ized way, with the first staging CT scan not older than 6
weeks before start of treatment. Copies of initial CT scans
and those showing response were evaluated centrally.
Quality of Life
QoL questionnaires (European Organization for Re-
search and Treatment of Cancer-QLQ-C30) were filled out at
regular intervals.
Blood Tests
Standard hematological, chemical, and liver function
tests were taken. Renal function was assessed by Iohexol or
Cr-ethylenediaminetetraacetic acid clearance, or when un-
available, creatinine clearance was calculated using the Cock-
roft-Gault equation.
Follow-Up Investigations
Before each new treatment cycle, there was a clinical
evaluation and blood tests were taken. Evaluation before 4th
cycle and 1 month after 6th cycle included chest radiograph,
CT scan of the chest and upper abdomen, spirometry, and
TABLE 1. Inclusion and Exclusion Criteria
Inclusion criteria:
1. Age 18.
2. Preliminary diagnosis of mesothelioma by the local pathologist.
Sufficient biopsy material for assessment by the panel of
pathologists.
3. All tumor stages. Tumor stage verified on a recent CT scan, not
older than 6 wk.
4. Performance status WHO 0–2.
5. Normal organ function, except if abnormal due to tumor
involvement.
Adequate bone marrow function with platelets 100  109/liter,
hemoglobin 100 g/liter.
Neutrophils 1.5  103/mm3 and WBC 3.0  109/liter.
Adequate renal function as indicated by Iohexol clearance (or Cr-
EDTA-clearance) 50 ml/min/1.73 m2 or serum creatinine: 1.5
 the upper limit of normal.
Adequate liver function with bilirubin 1.5 times upper limit of
normal, ASAT or ALAT 2 times upper limit of normal.
6. Written informed consent.
Exclusion criteria:
1. Previous treatment with anticancer chemotherapy of any tumor
within 10 yr.
2. Radiotherapy in the last 4 wk, except radiation of local lesions for
symptoms.
3. Any other active malignant disease within 5 yr, except basal or
squamous cell carcinoma of the skin or cancer of the cervix stage I.
4. Cardiomyopathy or any other cardiac disease with a dysfunction
NYHA class III or IV.
5. History of severe hypersensitivity reactions to any of the trial drugs.
6. Clinically significant hepatic disease.
7. Uncontrolled bacterial, viral, or fungal infection.
8. Pregnancy or breast-feeding. Patient of childbearing potential should
use contraceptive.
9. Confusion, disorientation, or any other condition (medical, social,
and/or psychological) which would prevent adequate information and
follow-up.
CT, computed tomography; WHO, world health organization; EDTA, ethylenedia-
minetetraacetic acid; WBC, white blood cell; ASAT, aspartate aminotransferase;
ALAT, alanine aminotransferase; NYHA, New York heart association.
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QoL. Every third month after the 6th cycle, the patients were
evaluated with chest radiograph, and CT scan of the chest and
upper abdomen if progress was suspected. Patients with
clinical suspicion of progressive disease were examined with
chest radiograph and/or CT scan at any time during the study.
Evaluation of Responses
The normal Response Evaluation Criteria in Solid Tu-
mors (RECIST) criteria cannot be used for valuation of
responses in mesothelioma, and the modified RECIST crite-
ria16 were not yet available when the study started. We
therefore decided to use our own criteria, which turned out to
be very similar to the later published modified ones. The
thickness of the pleura perpendicular to the chest wall was
measured in at least two defined levels of the CT scan, and
any measurable lymph node or other lesion was noted. A
partial response (PR) was defined as a diminishing of these
measurements (i.e., in one plane) in all measured places of
50% or more. Progression of disease was defined as an
increase of at least 25% in any of the measured lesions or the
appearance of new lesions. These criteria are in fact stricter
than the modified ones.16
Statistics
For the original planning of the study, the lowest limit
of therapeutic activity considered to be of interest was a
response rate of 15%. If one or more responses would be seen
among the first 25 patients, a response rate with a 95%
confidence interval of 15% can be determined with a mini-
mum of 45 patients, which was thus put as the goal. For the
QoL, Fisher‘s exact test was used. Actual time to response,
duration of response, TTP, and survival were measured for all
patients.
Ethical Committee
The study was approved by the local ethical committees
in all countries.
Study Drugs
Commercially available drugs were used according to
the producers’ instructions. The drugs were administered
every 3 weeks for 6 cycles. For the first three cycles, treat-
ment Level A according to Table 2 was administered as an
intravenous infusion on day 1 of each cycle followed by
gemcitabine alone, 1000 mg/m2, on day 8. First gemcitabine
was given in 250 ml NaCl during 30 minutes; next liposomal-
encapsulated doxorubicin was administered in 250 ml 5%
glucose during 1 hour; and finally carboplatin in 0.9% NaCl
during 30 minutes.
For the following 3 cycles gemcitabine, treatment
Level B according to Table 2 was administered as an intra-
venous infusion on day 1 of each cycle and gemcitabine, 800
mg/m2, on day 8.
If grade 4 neutropenia (neutrophils 0.5) or thrombo-
cytopenia (thrombocytes 25) developed anytime during the
preceding cycle, courses were withheld until both were re-
solved to grade 1 and the treatment was resumed with dose
reductions (from grade A to B, from grade B to C). If grade
2 to 3 neutropenia (neutrophils 0.5–1.4) or thrombocytopenia
(thrombocytes 100) developed, the drugs were withheld 1
week until both were resolved to grade 1 (neutrophils 1.5
and thrombocytes 100), after which study treatment was
resumed. If prolonged bone marrow toxicity (grade 1
during 3 weeks) developed, the patient would receive no
more cycles.
Six cycles were given, unless there was progressive
disease, too high toxicity, or other reasons to discontinue
treatment. If there was a good response and the patient and
the treating doctor so agreed, treatment could be continued
with further courses. If progression occurred after end of
treatment, treatment could be resumed, either with the
study drugs or some other therapy according to the treating
doctor’s discretion.
Concurrent Medications
Cytokines were not used prophylactically, but were
allowed under specific circumstances. Prophylactic anti-
emetics were administered at the discretion of the treating
physician. 5HT3-receptor antagonists and cortisone were
recommended.
RESULTS
Basic Data
Enrollment started in January 2001, and ended in De-
cember 2003. In all, 184 patients were included. Eleven
patients were excluded, either because the pathology panel
disagreed on the diagnosis or sufficient material for evalua-
tion was not available (8 patients) or due to protocol violation
(3 patients), thus leaving 173 patients available for evalua-
tion. Of those, 84 were from Sweden, 50 from Norway, 29
from Denmark, and 10 from Finland (which country joined
the study late). Asbestos exposure, in most cases occupa-
tional, was reported by 127 patients (74.4%), and pleurodesis
had been performed before treatment in 54 patients (31.2%).
The mean age was 62.8 years, with a range of 38 to 83.
There were 16 women (9.2%). The subtype of mesothelioma
was epitheloid (EP) in 116 patients (65.5% of the subtyped
mesotheliomas), mixed (MX) in 21 (18.1%), and sarcomatoid
(SA) in 24 (20.0%). In 12 patients, no subtyping had been
done. Seventy-five percent of the men and 27% of the women
had been exposed to asbestos.
Two patients were lost to follow-up; one of them
moved to Germany after 13 months (he had a PR and was in
good shape); and one patient was followed in 36 months but
was then lost to follow-up. All the others were followed until
death or for at least 4 years.
TABLE 2. Study Drugs and Dosages
Treatment
Level
Gemcitabine
mg/m2
Carboplatin
AUC (Calvert)
Liposomal-Encapsulated
Doxorubicin (Caelyx)
mg/m2
A 1000 5 30
B 800 4 25
C 600 3 20
AUC, area under the curve.
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Toxicity and Treatment
In 74 patients, less than 6 courses were given. Eight
patients had only one course, 7 had two, 16 three, 21 four, and
22 five treatment courses. Discontinuing the therapy was due
to toxicity in 35 patients, progressive disease in 23, and other
causes in 16. Thus, in all, 99 patients (57.2%) were treated
with the 6 courses or more, 121 (69.9%) had at least 5
courses, and 142 (82.1%) at least four. Fifteen patients
wanted to continue treatment after six courses; the highest
number of courses given consecutively was 12.
The toxicity was mainly hematological (Table 3), es-
pecially thrombocytopenia. Three patients died of neutro-
penic sepsis, 2 after the first course and 1 after 4, these being
the only treatment-related deaths. Four more patients were
hospitalized due to neutropenic fever or pneumonia.
One patient committed suicide after the first course, and
in all 16 patients refused further treatment after one to 5
courses. Other reasons for stopping treatment was a cerebral
infarction, probably not related to treatment, and declining
general condition. Two patients had good responses and were
therefore admitted for surgery after three courses; both had
later relapses and succumbed to the disease.
Nonhematological toxicity was low, as seen from Table
3. Palmo-Plantar Erythema, which is a common side-effect of
liposomized doxorubicin and consists of reddish and sore
skin especially in feet and hands on pressure areas, was rare.
Grade 1, which is usually not a big problem, was reported by
7.5% of the patients and there were only few more severe
cases.
Responses
There were 56 responses (32.4%), 54 PR and 2 com-
plete response. In the EP subgroup, there were 41 PR and 2
complete response (37.1%), in the MX, 5 PR (23.8%), and in
the SA, also 5 PR (20.8%), respectively. A remarkable
finding was that some responses occurred quite late, and in 4
patients (all of the EP subtype) it was seen 4 to 6 months after
the last given course.
Survival
The median survival for the whole group was 13
months, with a 1-year survival of 52.3% (Figure 1, Table 3).
In the EP group (n  116), the median survival was 17
months; in the S subtype (n  24) it was 4.5 months and in
the Mixed (n  21), 8.5 months (Figure 2). Long-term
survivors (2 years) occurred almost exclusively with the EP
subtype, one exception being a patient with SA tumor who
died 27 months after treatment. Thirteen patients (7.5% of all
and 11.2% of the EP group) were alive more than 4 years (48
months); 6 were dead after 50, 51, 52, 52, 53, and 59 months,
respectively, and 7 were still alive at last follow-up at 51, 51,
54, 55, 61, 63, and 72 months, respectively. The 72-months
survivor was still a PR at last check-up.
Patients in the EP subgroup, stage 1–2, PS 0–1, and
aged 70 years or less, had the best median survival of 22
months (Figure 3).
Time to Progression (TTP)
TTP was recoded in 168 cases. For all, the median TTP
was 8.2 months; for the EP subgroup, 10 months, and for the
MX and S, 6 and 4 months, respectively (Figure 4). Seven-
FIGURE 1. Total survival.
FIGURE 2. Survival according to subtype of mesothelioma.
FIGURE 3. Survival EP subtype, age 70 years or less, PS
0–1, stage 0–1.
TABLE 3. Worst Hematological and Nonhematological
Toxicity CTC Grade 2–4 (Percent)
CTC grade 2 3 4
Hematological toxicity
Lecopenia 17.9 38.7 9.2
Thrombocytopenia 9.8 25.4 28.3
Anemiaa 25.4 8.6
Nonhematological toxicity
Stomatitis 6.9 1.7
Nausea 9.8 0.6
Alopecia 2.3 1.1 1.1
PPEb 3.4 0.6
a All patients treated with transfusions.
b Palmo-Planar Erytema, see text.
CTC, common toxicity criteria.
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teen percent of the whole material and 23% of the EP group
had a TTP of 1 year or more.
Correlation Between Responses and Survival
The responses in the MX and SA subgroups were
short-lived. In the EP subgroup, there were enough responses
to make some correlations with survival, and there was a
tendency to longer survival in those who responded (Figure 4).
Pleurodesis
Fifty-eight patients (33.5%) had a pleurodesis per-
formed before enrollment. It was somewhat more common in
the EP subgroup (37.2%) than in the MX and SA groups
(23.3%). The survival was not affected by pleurodesis having
been performed or not.
Asbestos Exposure
The men were exposed to asbestos to a much higher
degree than were the women (Table 3). There were no
significant differences between the subgroups.
Gender and Survival
The women generally lived longer in all groups. In the
116 patients with EP subgroup, the women had a median
survival of 25 months, while this figure for the men was 17
months.
Second Line (and Further) Treatment
Many patients were retreated either with the same drug
combination or with Pemetrexed and a platinum drug at
progression, some repeatedly, and again responses were seen.
Unfortunately, these data were not systematically registered.
DISCUSSION
This is as far as we are aware the largest phase II study
on MPM ever published. After reaching the first goal of about
50 patients, there were many responses, and the logical
continuation would have been a randomized study with a
standard treatment. The problem was that no such treatment
at the time existed. After discussions with the ethical com-
mittees, it was decided to enlarge the study and include more
patients. Until the pemetrexed randomized study15 appeared
enrollment continued, making the present study a very large
phase II one.
The Pemetrexed study is the only existing phase III
randomized study on treatment of mesothelioma. Four
hundred fifty-six patients were randomized to either cis-
platin alone or to cisplatin combined with Pemetrexed.15
The study proved that cytostatic treatment of mesotheli-
oma can prolong survival: median survival time for the
pemetrexed/cisplatin arm was 12.1 month versus 9.3
months in the cisplatin only arm. Pemetrexed and a plati-
num drug is now standard treatment for malignant me-
sothelioma world wide.
The three-drug combination treatment in the present
study had a fairly low toxicity and was well tolerated. The
QoL remained very good during treatment. There were many
responses, and TTP and survival were long. However, given
that it is only a large Phase II study, we cannot conclude that
this treatment is superior to any other; this would require a
Phase III study including some hundreds of patients, which
unfortunately is beyond the economic possibilities of the
Nordic groups.
In this study, a large number of well-defined patients
have been treated and followed for a long time, and in
particular there are fairly large numbers of patients with EP
subtype in early stages. “Radical” surgery has traditionally
never had any large place in the treatment of MPM in
Scandinavia because of the lack of medical evidence. Thus, only
a small number with very early stages of disease and with the
best performance status were operated rather than included in
this study. This makes it is difficult to compare this study with
others, where the criteria for “operability” are wider.
Subtypes
This study again demonstrates that the subtype of MPM is
a very important prognostic factor. In any study, the subgroups
should be presented separately. In particular, the EP subtype not
only has the best prognosis, it is also the subtype that responds
best to any kind of treatment.
Responses
We actually used stronger criteria than the modified
RECIST ones.16 A decrease of 50% in pleural thickness for
response is higher than the 30% in the RECIST. For progress,
25 and 20% were used, respectively.
The value of responses as the first end point in studies
of MPMmight overlook important clinical improvements and
FIGURE 4. Time to progression according to subtype of
mesothelioma.
FIGURE 5. Correlation between responses and survival, EP
subtype.
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even prolongation of life. As seen from Figure 5, there is a
crude correlation between responses and survival in the EP
subgroup (but not in the non-EP groups), but in the literature,
there are very diverging results (Table 4). The studies are not
comparable as the selection of patients varies in different
studies. The aim of the comparison is merely to point out the
discrepancy between responses and survival.
Late Responses
A discrepancy between responses and survival is
known from other malignant tumors. One example is pan-
creas carcinomas; local inflammatory reactions induced by
the tumor makes it difficult to estimate tumor size and
responses may be underestimated, and patients with SD are
considered to be responders.17,18 Mesotheliomas can also
contain large amounts of fibrous tissue, which might only
slowly resolve once the tumor cells have been diminished.
This could explain the curious finding of responses many
months after the last treatment course.
Implications for Surgery and Combination
Treatments
This is to our knowledge the first study with a fairly
large group of patients with good prognosis, i.e., EP sub-
group, early stages, and good PS, which has not been sub-
mitted to surgery. In the subgroup of 51 patients aged 70
years or less with these criteria (Figure 3) the 1-year survival
was 88% and 3 years 18%, with a median survival of 21.5
months. In a recent study of 100 patients who had extrapleu-
ral pneumonectomy (EPP) with or without following radia-
tion, the median overall survival was only 10.2 months (but
one third of the patients was of the non-EP type). In a surgical
nonnode, EP subgroup of 18 patients, the median over-all
survival was 28 months, and the 3-year survival 41%.19 All
patients had mediastinoscopy before being submitted to EPP,
but despite this 54% of the patients had N1 or N2 nodes at
thoracotomy and were excluded. Thus, this small subgroup
was much more heavily selected than in the present study.
In another recent large retrospective study, 945 patients
were described from a 15-year material in a large referral
center in New York.20 The overall results are strikingly
similar to those in the present study: median survival for
epithelial subgroup, 16.3 months (17 months in the present
study); the MX group, 9.5 months and 8, 5; and the SA, 6 and
4.5, respectively. EPP alone was performed in 177 patients,
with a median survival of 10.3 months, and multimodality
therapy in 207, with median survival of 20.1 month.
Some data from these and other studies have been
compiled in Table 5. Studying these figures, one cannot but
agree with a recent editorial25 that “the benefit from surgical
resection is questionable,” and that whether addition of ra-
diotherapy will improve the results is also unproven. Ran-
domized studies are therefore urgently needed.
CONCLUSIONS
Treatment with a combination of pegylated liposomal-
encapsulated doxorubicin, gemcitabine, and carboplatin in
MPM is feasible, has a low toxicity, results in a high number
of responses, and is associated with good TTP and survival.
Some patients have a delayed response which is seen many
months after treatment. The results from patients with EP
subtype and good performance status illustrate that random-
ized studies are necessary to evaluate surgical and multimo-
dality treatment of this disease.
TABLE 4. Comparisons Between Some Studies Mentioned
in the Text
Study n
Responses,
Percent
Median
Survival,
mo
This study 171 32 13
Caelyx alone10 33 6 13
Gemcitabine  cisplatin14 21 48 10
Gemcitabine  cisplatin17 25 16 10
Alimta  cisplatin15 226 41 12
Cisplatin alone15 222 17 9
TABLE 5. Some Studies Where Surgery and/or Multimodality Therapy Has Been used Compared to the Present Study
Reference Treatment Subtypes, n Median Survival, mo Comments
This study C All, 173 13
EP, 116 17
EP, selected 22
21 EPP  RT  C All, 176 19 Those who survived surgery only
22 EPP  RT All, 61 17
23 EPP  RT All, 26 18 Perioperative deaths excluded
19 EPP All, 100 10
EPP  RT All, 65 14
EPP  RT EP, 18 28 Pathologically node-negative
20 EPP All, 177 10 Selected by PET-CT  mediastinoscopy
Multimod All, 207 20 Selected by PET-CT  mediastinoscopy
24 Dec  RT  C All, 49 26 Also received interleukin-2
C, Chemotherapy; EPP, extrapleural pneumonectomy; Dec, decortication; RT, radiotherapy; EP, epitheliod subtype; CT, computed tomography; PET, positron emission
tomography.
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